by Francisca Peixoto | Jan 5, 2024 | Uncategorized
As we start the new year, LifeLink Ventures releases its 2023 Annual Biotech Report. We wish to connect private investors with emerging technologies that address global health challenges. To do so, first we must bring our investors closer to the biotech world. Learn...
by Francisca Peixoto | Dec 20, 2023 | Uncategorized
Our portfolio company Eveliqure Biotechnologies announces, on December 18th 2023, that it has launched a Clinical Trial for their Shigellosis and ETEC vaccine in Bangladesh. Eveliqure is a clinical-stage Austrian biotechnology company that has developed a proprietary...
by Francisca Peixoto | Dec 7, 2023 | Uncategorized
Boston Consulting Group (BCG) made an interesting article showing #DeepTech VC funds have similar returns to traditional VC, despite the high complexity and cash needs of building hardware and #biomolecules. #DrugDevelopment has no shortage of complexity or investment...
by Francisca Peixoto | Oct 19, 2023 | Uncategorized
Our portfolio company Macomics just appointed Kevin Lee as Independent Non-Executive Director. Kevin brings over two decades of invaluable biotech and pharma experience to Macomics’ team. He has been CEO at Bicycle Therapeutics since 2015, steering the company...
by Francisca Peixoto | Oct 16, 2023 | Uncategorized
Pablo holds a Master’s degree in Stem Cells and Regenerative Therapies from King’s College London, and a Bachelor’s degree in Biomedical Sciences from Royal Holloway University of London. His academic journey has equipped him with a thorough understanding of the...
by Francisca Peixoto | Sep 13, 2023 | Uncategorized
Our portfolio company Macomics published in Nature’s Biopharma Dealmakers September issue withe the article “Harnessing the Power of Macrophage Drug Discovery”. The article provides an overview of the company and the power and application of our...
